Head-to-head evidence
CPT31 vs Lipovirtide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV gp41 · full HIV pipeline
CPT31
Developed by Navigen
NCT04672083 · Phase 1 · completed
The study randomly assigned healthy volunteers to CPT31 or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. It reported that no participant in any group, active or placebo, had a serious adverse event, but the study measured only safety and drug levels in healthy volunteers rather than any HIV outcome.
Lipovirtide
Developed by Shanxi Kangbao Biological Product
NCT06061536 · Phase 2 · completed
The study was randomized and included an active DTG comparator, but it was open-label, enrolled 64 participants across four groups, and used viral suppression as a surrogate laboratory endpoint rather than a hard clinical outcome. Because the primary comparison and its statistical result are not available, the findings cannot be judged as having met or missed the endpoint.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CPT31's landscape · Lipovirtide's landscape